Hot Features
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structu... Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorpora.ted in 2005 and is headquartered in Dublin, Ireland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 480 | 0.0001 | CS |
| 12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0001 | 1.0E-6 | 377 | 9.997E-5 | CS |
| 26 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 640 | 0.00015374 | CS |
| 52 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 1133 | 0.00010892 | CS |
| 156 | -1.2899 | -99.992248062 | 1.29 | 1.35 | 1.0E-6 | 2984 | 0.45010822 | CS |
| 260 | -1.2899 | -99.992248062 | 1.29 | 1.35 | 1.0E-6 | 2984 | 0.45010822 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.